Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
GSK3 modulation in acute lung injury, myocarditis and polycystic kidney disease-related aneurysm

Wei-Lun Liu\textsuperscript{a,b,c,}, Fu-Tien Chiang\textsuperscript{d,e,}, Juliana Tze-Wah Kao\textsuperscript{f,g}, Shih-Hwa Chiou\textsuperscript{h,i,}, Heng-Liang Lin\textsuperscript{c,k,*}

\textsuperscript{a} School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan \\
\textsuperscript{b} Division of Critical Care Medicine, Department of Emergency and Critical Care Medicine, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan \\
\textsuperscript{c} Genomic Research Center, Academia Sinica, Taipei, Taiwan \\
\textsuperscript{d} Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan \\
\textsuperscript{e} Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan \\
\textsuperscript{f} Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan \\
\textsuperscript{g} Division of Nephrology, Department of Internal Medicine, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei, Taiwan \\
\textsuperscript{h} Division of Nephrology, Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan \\
\textsuperscript{i} Division of Cardiology, Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan \\
\textsuperscript{j} Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan \\
\textsuperscript{k} Genomic Research Center, Academia Sinica, Taipei, Taiwan \\
\textsuperscript{l} Division of Fund Managing, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan

\textbf{ABSTRACT} \\
GSK3 are involved in different physical and pathological conditions and inflammatory regulated by macrophages contribute to significant mechanism. Infection stimuli may modulate GSK3 activity and influence host cell adaption, immune cells infiltration or cytokine expressions. To further address the role of GSK3 modulation in macrophages, the signal transduction of three major organs challenged by endotoxin, virus and genetic inherited factors are briefly introduced (lung injury, myocarditis and autosomal dominant polycystic kidney disease). As a result of pro-inflammatory and anti-inflammatory functions of GSK3 in different microenvironments and stages of macrophages (M1/M2), the rational resolution should be considered by adequately GSK3.

1. Introduction

It has been a critical field for GSK3 as a major regulator of peripheral inflammatory responses. GSK3 also participates in stimulus-induced production of several cytokines that are related to inflammatory cell migration and disease symptoms. GSK3, a serine/threonine protein kinase signaling molecule, is widely expressed in versatile cell types. GSK3 is responsible for glycogen metabolism and involved in downstream of insulin signaling. Insulin-mediated signaling could be an activator of PI3K and, subsequently phosphorylation of both GSK3\textsubscript{α} (Ser21) and GSK3\textsubscript{β} (Ser9) \cite{1}. GSK3 is rapidly phosphorylated and inhibited by the activation of the phosphoinositide 3-kinase (PI3K) pathway, contributing to depression of glycogen \cite{2}. Two isoforms in mammalian cells are GSK3\textsubscript{α} (51 kDa) and GSK3\textsubscript{β} (47 kDa) with 85% overall structural similarity and the kinase domains shares 97% identity. However, only 36% identity found on the C-terminus \cite{3}. In general the functions of GSK3 are dependent on tyrosine residues phosphorylation (Tyr279 for GSK3\textsubscript{α} and Tyr216 for GSK3\textsubscript{β}) as active forms. In contrast, the serine residues phosphorylation (Ser21 for GSK3\textsubscript{α} and Ser9 for GSK3\textsubscript{β}) are a suppressive status \cite{4}. More than 80 proposed substrates has been reported to interact with GSK3\textsubscript{β} \cite{5}. GSK3\textsubscript{β} can be negatively regulated through phosphorylation on Ser9 by different kinases, for example MAPK, ERK or Akt \cite{6}. In monocytes, PI3K/Akt-dependent inhibition of GSK3\textsubscript{β} activity can regulate Toll-like receptor (TLR)-dependent activation \cite{7}. Further mechanism reveals the insulin-mediated signaling pathway as an activator of PI3K and subsequently a phospho-inactivator of both GSK3\textsubscript{α} (Ser21) and GSK3\textsubscript{β} (Ser9) \cite{8}. Even GSK3\textsubscript{α} and \textsubscript{β} share highly structural similarity, GSK3\textsubscript{β} null mice die during late embryogenesis with cardiac abnormalities \cite{9,10}, however, GSK3\textsubscript{α} null mice are survival with elevated insulin
sensitivity [11].

2. GS3 role on inflammation

GS3 activity is necessary for full stimulation of the production of several pro-inflammatory cytokines, such as IL-6, IL-1β, and tumor necrosis factor (TNF) in the peripheral blood mononuclear cells [7]. Moreover it has been found that Toll-like receptor activation in monocytes may induce interleukin 10 production and accompany with reduced level of pro-inflammatory cytokines after GS3 and NF-κB inhibition [7]. Even studies demonstrate that GS3 is necessary for the full transcriptional activity of NF-κB [9], GS3 may support NF-κB transcriptional activity in a promoter-specific manner, indicating that GS3 selectively modulates subset NF-κB mediated genes [12]. For example, NF-κB-mediated expression of IL-6 and monocyte chemotactrant protein-1 (MCP-1) require GS3β for efficient expression, but not IκBα and macrophage inflammatory protein-2 [13] [14]. This selective action of GS3β on NF-κB-induced gene expression is of significance to explore the anti-inflammatory utility of GS3 inhibitors with differently NF-κB responses.

Decreased phosphorylation of NF-κB, JNK, ERK and P38MAPK in LPS-stimulated macrophages is related to IL-10-dependent manner by GS3β phosphorylation [15]. In addition, TLR signaling can induce the phosphorylation of GS3β through the PI3K/Akt signaling pathway [16]. By means of increasing the production of IL-10, it results in reduction of phosphorylation of NF-κB, JNK, ERK and P38 MAPK in LPS-stimulated macrophages. The enhancement of GS3β phosphorylation (inactivation) via PI3K/Akt is involved in the methane-rich saline-induced production of IL-10. However, another studies indicate that 6-bromoinodirubin-3-oxime (BIO) inhibits GS3 activity and then triggers a feedback regulatory loop aiming to restore physiological GS3 activity. This loop results in gsk-3β gene and protein upregulation and it also reduces the levels of the inhibitory GS3α (Ser21) and GS3β (Ser9) [15].

3. GS3 in lung inflammation

Recently the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is leading to the global outbreak of coronavirus disease 2019 (COVID-19). The clinical manifestation is involved in acute respiratory distress syndrome (ARDS). Currently many trials are exploring the clinical feasible means to manage it [17]. Particularly chloroquine is an existing medicine with approved indication for anti-malarial use. It reveals inhibitory effect on SARS-CoV-2 [18]. In view of the intracellular versatile functions of GS3, viruses could likely leverage this important kinase to multiplicate in host cells. It has been shown that multiplication of the SARS coronavirus depends on GS3-mediated phosphorylation of the nucleocapsid (N) protein which is a necessary process for viral replication [19]. In addition, it was shown that GS3β promoted the life cycle of influenza virus through facilitating the viral entry step [20]. GS3β also participates in other viral multiplication, such as HCV, HIV, coxsackievirus group B3 (CVB3) and venezuelan equine encephalitis virus [17] [20,21] [21]. As for bacterial infection, inhibition of GS3β-related regulations by chloroquine-modulated PI3K/Akt signaling may increase survivability in B. pseudomallei-infected mice. The underlying mechanism appears high level of phosphorylated Akt (Ser473) and GS3β (Ser9) in liver samples of mice administered with chloroquine and decreased phosphorylation of NF-κB p65 (Ser536). Further analysis showed that chloroquine may reduce pro-inflammatory cytokines (TNF-α, IFN-γ, IL-1β and IL-18) and increase levels of anti-inflammatory cytokines (IL-4 and IL-10) in B. pseudomallei-infected mice [22].

3.1. GS3 in acute respiratory distress syndrome

Alveolar neutrophils and macrophages are of significance in lung immune regulations. Neutrophils exhibit the acute phase effector and migrate into the inflammatory sites by mediation of versatile cytokines and chemokines [23]. Neutrophils represent over 50% of all circulating leukocytes and, mostly in the pulmonary pool [24]. As injury occurred in lung, the activated neutrophils exhibit the process of degranulation and to release intracellular enzyme, such as neutrophil extracellular traps (NETs), which is composed of chromatin fibers mixed with antimicrobial proteins [25]. Particularly, increasing studies have been working on NETs induced by different stimuli-triggered neutrophil activations (such as LPS, calcium ionophore A23187 and phorbol 12-myristate 13-acetate) [26]. Inhibition of GS3β decreases NETs production, anti-inflammatory functions (such as LPS, calcium ionophore A23187 and phorbol 12-myristate 13-acetate) [26]. Inhibition of GS3β diminishes LPS-induced neutrophil activation, lung injury as well as reduced level of pulmonary edema, TNF-α, MIP-2 and HMGB1. The underlying mechanism revealed that GS3β-dependent phosphorylation of threonine 479 on AMPK is associated with pT1172 dephosphorylation and inactivation of AMPK. Moreover, GS3β-dependent inhibition of AMPK in LPS-treated neutrophils activation is dependent on IKK1/2 [27]. Given that AMPK has anti-inflammatory functions [28], it appears that GS3β inhibitors (BIO or SB216763) prevent Thr172-AMPK dephosphorylation then attenuates proinflammatory cytokine production [29] and protection from bleomycin-induced lung injury [30] (Fig. 1).

Protein-rich edema is frequently manifested in patient with ARDS. Impairment of edema removal is associate with alveolar hypoxia and systemic hyoexemia [31]. Protein clearance from the distal air spaces is facilitated by an the regulation of megalin (LRP2), belonging to the low-density lipoprotein (LDL)-receptor superfamily [32]. Studies have shown a detrimental role of GS3β during ARDS via inhibition of alveolar epithelial protein transport. Thus megalin is negatively regulated by GS3β. Tidelgulab and valproate (GS3β inhibitors) may reduce alveolar protein concentrations and suppress acute lung injury [33]. Similarly, the observation of utilizing ventilator-induced ARDS in mice, it appears that increased mRNA and protein expression of GS3β, implying the GS3β role in edema removal [34] (Fig. 1). To further analyze alveolar fluid composition, albumin is disclosed to be the abundant protein and clathrin-mediated endocytosis and transcytosis is responsible albumin transferring [32]. Other study shows that activation of GS3β by its dephosphorylation at Ser9 inhibits albumin uptake and the phosphatase PP1 is responsible in alveolar epithelial cells. In vitro studies show that TGF-β treated alveolar epithelial cells inhibiting uptake of albumin and decreases megalin abundance on the plasma membrane. It shows that GS3β phosphorylates megalin leading to its subsequent downregulation [35]. Moreover Acyl-CoA:lysophosphatidylcholine acyltransferase 1 (LPCAT1) is a key enzyme in the synthesis of dipalmitoylphosphatidylcholine, an important surfactant. In LPS-induced ARDS experimental model, LPCAT1 is phosphorylated by GS3β, then ubiquinated and targeted for degradation [36].

In order to relief ARDS, it appears a positive outcome by inhibition strategy of GS3β through inhaling aerosolized insulin, [37]. In acute necrotizing pancreatitis (ANP)-elicited lung injury, protective effect of p-GS3β (Ser9) inhibits by treatment of GS3β inhibitors (TDZD-8 or SB216763) [38]. Since NF-κB could be phosphorylated by GS3β and lead to transcriptional responses, inhibitors of GS3β may decrease the activation of NF-κB and then reduce downstream gene expression (IL-β, IL-6, and TNF-α) [29]. In addition, cell adhesion related signals such as ICAM-1 modulated leukocyte adhesion and migration in acute pancreatitis and higher level of ICAM-1 were indicated in lung tissues [39-41]. Converging all evidences reveal the axis of GS3β/NF-κB/ ICAM-1 pathway of leukocyte infiltration in lung injury (Fig. 1). Meanwhile, by applying GS3β inhibitors (TDZD-8 and SB216763 pretreatment,1 mg/kg) to treat ANP rats, it is found that the increased expression of p-GS3β(Ser9) and IL-10 levels in lung [38].

3.2. GS3 modulation by cholinergic signaling

As ARDS patients rescued by ventilated treatment, it frequently exhibits strong respiratory efforts. These respiratory efforts may result
satracurium and ventilation reveals reduction of the epithelial-mesenchymal transition (EMT) [45,46]. Co-treatment of cisatracurium negatively regulates the expression of the E-cadherin and also inhibits GSK3 kinase activity [44]. In line with other studies indicate that GSK3 kinase activity negatively regulates the expression of the E-cadherin and also inhibits epithelial-mesenchymal transition (EMT) [45,46]. Co-treatment of cisatracurium and ventilation reveals reduction of the inflammatory injury by decreased HMGB1 expression in lung tissue [47]. It has been indicated that HMGB1 could trigger inflammatory cytokines via macrophages and result in onset of acute lung injury [48]. HMGB1 participates in lung inflammation and could modulate AKT/GSK3β/β-catenin signaling pathways in human bronchial epithelial cells [49]. In parallel, by increasing endogenous cholinergic activity through acetylcholinesterase inhibitor (physostigmine) treatment at a low dose (0.1 mg/kg), it shows a rapid increases of both phospho-Ser21-GSK3β and phospho-Ser9-GSK3β in mice [50].

3.3. GSK3β on cell migration

GSK-3 regulation is known to be involved in cell migration. Elevated PI3K and p-Akt expression in the lung tissue by propofol treatment of LPS-challenged rats resulted in the reduction of acute lung injury. This protective effect is accompanied with prolonged survival, decreased the concentrations of protein, TNF-α, and IL-6. The activated PI3/Akt induced by propofol may attenuate GSK3β activity [51] (Fig. 1). Propofol is a potent intravenous anesthetic and sedative agent widely used to facilitate intubation and ventilation [52]. Propofol suppresses acute lung injury (ALI) by influencing migration, phagocytosis, and oxidative ability of macrophages [53]. Cell migration is considered to participate in inflammatory responses. GSK-3 has also been demonstrated to regulate microtubule stability through phosphorylation of three microtubule/tubulin-associated proteins, Tau, microtubule-associated protein 1B, and collapsin response mediator protein 2 [54,55]. Paxillin (PXN) is a 68-kDa focal adhesion-associated protein that plays an important role in controlling cell spreading and migration. PXN has been described as regulators of macrophage migration [56]. GSK-3 phosphorylates PXN (S126/S130) during the process of macrophage migration after LPS treatment and reversely regulated by the mutation of PXN with S126A/S130A substitutions [57]. Additional studies reveal miR-375 derived from cancer cells influences macrophage migration by enhanced PXN and tensin 3 (TNS3) mRNA levels [58]. LPS-stimulated macrophages results in PXN-mediated cytoskeleton changes through ERK/GSK3β pathway [57]. Other molecular mechanisms involved in the protective function of propofol on brain and liver are PI3K/Akt pathway activation [59] and sustaining the mitochondrial function by GSK3β regulation, respectively [60].

3.4. GSK3β alteration by antibiotics with immune modulation effects

Group B streptococci are Gram-positive bacteria for pneumonia, sepsis and particularly in newborns meningitis. S632A3 is a glutarimide antibiotic with immune inhibitory effect on LPS-stimulated macrophages. This inflammatory suppression occurs via inactivation of GSK3β and the differential promotion of CREB–CBP interactions over NF-κB signaling and leads to increased IL-10 production [61] (Fig. 1). It has been indicated that phosphorylated CREB (Ser133) interacted with CBP could reduce NF-κB activity [62–64] [65]. Since GSK3β can inhibit DNA-binding activity of CREB [12], GSK-3β inhibition augments the binding of CREB (Ser133) and suppresses the binding of NF-κB p65 (Ser276) to the nuclear coactivator CBP. This mechanism accounts for the inactive form of GSK3 to be involved in IL-10 production by means of the transcription ability of CREB within LPS-stimulated monocytes [7]. Of particular the M2 macrophage produced IL-10 is indicated to mediate via CREB transcriptional activity [66] (Fig. 1). Macrolides (erythromycin and azithromycin) have improved ARDS mortality and shortened usage of mechanical ventilation [67] and anti-inflammatory M2 macrophage production [68]. Several other antibiotics, minocycline, may influence GSK3β activity [69]. Furthermore, it has been indicated that PI3K/Akt and GSK3β pathway is responsible for protective effect of minocycline in ketamine-induced neural stem cell injury. The phosphorylated GSK3β level restored after minocycline treatment in ketamine-induced neural stem cell injury. In contrast, PI3K inhibitor (LY294002) reduces the protective effect of minocycline [70].

Berberine is a natural alkaloid isolated from plants and has long been used in botanical medicines. Berberine effectively alleviated lung injury by reducing pulmonary edema and neutrophil infiltration via...
activation of Nrf2 signaling [71] (Fig. 1). Furthermore, berberine reduces LPS-induced lung injury in a Nrf2 dependent manner [72]. GSK3β may phosphorylate Nrf2 and trigger ubiquitination-mediated degradation. As a result, attenuating GSK3β activity provides further feasibility for Nrf2 responsive transcription [73]. Inhibiting GSK3β by BIO treatment increases the expression of MDR genes and the drug efflux activity [74]. Berberine reduces production of pro-inflammatory cytokines in various cell lines via inhibiting NF-κB pathway [75,76]. In addition, reduced phosphorylation level of PI3K/Akt, ERK, and GSK3β also involves in berberine-regulated effects [77]. Moreover the ATP-binding cassette (ABC) transporters express in lung (particularly alveolar macrophages, airway smooth muscle cells, epithelial cells) participate in inflammatory responses [78]. Wnt signaling appears critical and increase p-glycoprotein (p-gp) transporter (ABCb1) by Wnt agonist (1.5–20 uM AMBMP) [79]. Other GSK-3β inhibitors such as 1-aza-kenpaulone (0.05–0.5 uM), BIO (0.1–1 uM) and LiCl (5000–10,000 uM) may increase MDR protein expression [79] [80]. Comparable effect of berberine-associated upregulated MDR expression were found in oral, gastric, colon and liver cancer cell lines [81] [82], suggesting the axis of PI3K/Akt/ERK/GSK3β/Nrf2/MDR signaling involved in berberine-mediated alleviation of pulmonary edema and injury [71] [72].

4. GSK3β-mediated inflammation in heart

Base on the observation of GSK3β null mice embryogenesis, it implies that GSK3β modulation participates important role of heart physical functions and related diseases [83]. Myocarditis remains a leading cause of heart failure (HF) in children and young adults [84]. From the manifestation of coxsackievirus B3 (CVB3)-positive myocarditis, endomyocardial biopsy results demonstrate higher proteins expression of S100A8 and S100A9. A decrease in myocardial expression of S100A8 and S100A9 has been indicated that IL-17 and HMGB1 could aggravate the cardiomyocyte apoptosis and autophagy. Extracellular HMGB1 was reported to cause cardiac remodeling, hypertrophy, repertusion injury and myocardial fibrosis [92,93]. Since autophagy is regulated by autophagy-related proteins, such as, LC3-II/LC3-I and Beclin-1 [105], the increased ratio of LC3-II to LC3-1 and the Beclin-1 expression are of significance in H/R group. Thus, it reveals that HMGB1/IL-17A/autophagy signaling is involved in cardiomyocytes injury [106]. Many studies have focused canonical wnt/β-catenin pathway on myocardial infarction and cardiac fibrosis [107]. The dilated cardiomyopathy is reported to associate with atrial fibrillation [108]. Canonical wnt/β-catenin pathway could induce several types of MMPs via modulation of the Axin, APC, and GSK3β protein complex after cardiac injury [109] [110]. The activation of the GSK3β/β-catenin pathway was ever reported to contribute to HMGB1-induced chondrocyte expression of matrix metalloproteinases (MMPs) [111]. The increased phosphorylated inactive GSK-3 has participated in the cytoplasmic accumulation and translocation of β-catenin into the nucleus, resulting in the expressions of downstream target genes [112]. In murine macrophage RAW264.7 cells, GSK3 participates in LPS-induced MMP-9, IL-1β and IL-6 gene expression [113]. Extracellular HMGB1 also induces EMT involved Akt phosphorylation, GSK3β inactivation, nuclear translocation of β-catenin and expression of receptor for RAGE [49]. These studies reveal a mechanism of extracellular HMGB1 in EMT through Akt/GSK3β/β-catenin/MMP/RAGE signaling pathway in cardiac remodeling. However, emerging evidences report that intracellular HMGB1 has an additional functions since attenuation of nuclear HMGB1 result in the detrimental conditions [114–116] (Fig. 2). Intriguing, studies found cardiac nuclear HMGB1 inhibited phosphorylation of ATM and subsequent activation of ERK1/2 and NF-kB signaling [117]. Excessive DNA damage causes phosphorylation of ATM and patients by using left ventricular assist device decreased the expression of p-ATM in cardiomyocytes [118], indicating a different aspect of protective axis by nuclear HMGB1/ATM/ERK/NF-kB signaling.

Neutrophils play a critical role for cardiac inflammation in the experimental autoimmune myocarditis (EAM), indicating relevant
features of post-viral heart disease [119,120]. The sustained cardiac inflammation results in tissue remodeling and eventually DCM. Neutrophils slow rolling on venule of inflamed sites require lymphocyte function-associated antigen 1 (LFA-1) and the macrophage 1-antigen (Mac-1) [121]. After neutrophils adhesion, NETs formation participates function-associated antigen 1 (LFA-1) and the macrophage 1-antigen in [122]. However, recent results appear that blocking LFA-1 by its neu-

heart weight/body weight ratio [123]. It has been found that more progenitor cells on the model of EAM, accompanied with an increased 80+ macrophages, CD4+ T cells, Ly6G+ neutrophils, and CD133+ features of post-viral heart disease [119,120]. The sustained cardiac inflammation results in tissue remodeling and eventually DCM. Neutrophils slow rolling on venule of inflamed sites require lymphocyte function-associated antigen 1 (LFA-1) and the macrophage 1-antigen (Mac-1) [121]. After neutrophils adhesion, NETs formation participates function-associated antigen 1 (LFA-1) and the macrophage 1-antigen in [122]. However, recent results appear that blocking LFA-1 by its neu-

4.3. GSK3β modulated in cardioprotective effect

Since activated M1/HMGB1/IL17 axis involves in cardiomyocyte injury, the modulation of M1 macrophage is conceived as a rational target for treatment. Propofol is a clinical approved medicine for an-

Fig. 2. The role of GSK3β on myocarditis and dilated cardiomyopathy. Coxsackievirus B3 (CVB3) infection induces myocardial expression of S100A8/S100A9 and leads to activation of NLRP3 inflammasome/caspase-1/IL-1β signal pathway. GSK3β cooperates with JNK1 to trigger NLRP3 inflammasome-related myocarditis. Activated M1 macrophages secreting HMGB1 may involve in dilated cardiomyopathy. Propofol inhibits GSK3β by phosphorylation and prevents M1 macrophage polarization. Berberine protects myocytes via AMPK activation or Nrf2 mediated inhibition of M1 macrophages. Berberine triggers M2 macrophage polarization, MDR1 expression and anti-inflammatory response.

4.2. GSK3β role on cholinergic signaling in heart

The role of the parasympathetic nervous system in modulating inflammation has been recently established and considered as cholinergic antiinflammatory pathway. Stimulation of vagal efferent in the spleen results in the local release of acetylcholine that inhibits the release of proinflammatory cytokines by macrophages [128,129]. In general, there are two major sources of cholinergic signaling in heart: neuronal cholinergic signaling mediated by the release of acetylcholine from the vagus nerve, and the nonneuronal cholinergic system. The latter one has been described recently and it is mediated by the release of acet-

ylcholine by cardiomyocytes [130,131]. Phystostigmine is a rapid and short-acting inhibitor of acetylcholinesterase. It appears that the low dose (0.1 mg/kg) of phystostigmine administration results in rapid increases of both phospho-Ser21-GSK3β and phospho-Ser9-GSK3β in the hippocampus, cerebral cortex, and striatum, with a maximal effect occurring after 15 min [50]. Acetylcholine is released by cardiomyocytes attenuates the detrimental effects, such as oxidative stress, and modulates energy metabolism by enhancing glucose utilization in the heart [132]. Moreover, the immunomodulatory role of cholinergic signaling resulted in increased recruitment of anti-inflammatory cells to the heart and that the increased influx of FOXP3+ Tregs resulted in macrophage polarization toward M2 cells [133].
doxorubicin-induced cardiac injury [139]. Moreover, AMPK and Nrf2 pathways is considered to be required for anti-inflammatory effect of berberine in LPS-stimulated macrophages [140](Fig. 1). Nrf2 inhibits the transcriptional induction of a subset of M1-induced genes (such as IL6 and IL1β) without going through ARE modulation [141]. As a result, the in vivo underlying mechanism of inhibitory response of berberine could attribute to inhibit M1 polarization by Akt1/AMPK/Nrf2/NF-κB signaling pathway [142]. Interestingly, it has found that M2 macrophages appear higher level expression of MDR1 than M1 macrophages [143]. Nrf2 is involved in upregulation of MDR1 and anti-inflammatory after berberine treated DSS-Induced Colitis [144]. Polarized M2 macrophages were appeared after a regimen of berberine administration (100 mg/kg/d for 16 weeks) in adipose tissue [145]. Thus, the Nrf2-mediated transcriptional inhibition is controlling a suppressive role for M1 macrophages polarization. In contrast, GSK3/Nrf2 signaling facilitates M2 macrophages skewing [141](Fig. 2).

Many studies appear GSK-3 signaling in cardiac myocyte proliferation since GSK-3 phosphorylates four glycogen synthase regulatory serine residues (Ser641, Ser645, Ser649, and Ser653) and results in inhibiting glycogen synthase activity [146]. Glycogen synthesis in cardiac muscle is critical for normal heart development and its impairment leads to congenital heart defects and death [147]. Inhibition of GSK-3 by BIO promotes proliferation in mammalian cardiac myocytes. Employing sustained delivery hydrogel of BIO and IGF-1, it promoted the proliferation of cardiac myocytes, promoted revascularization at the injury site and improved cardiac function.

4.4. GSK3β, MIF and MCP-1 in autosomal dominant polycystic kidney disease

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease, characterized by renal cysts and numerous extra-renal manifestations [148]. Mutations of GSK3β has been considered as a rational mechanism to reduce renal cyst expansion. The abrogation of GSK3β activity could be accompanied with decreased c-Myc/p-ERK/Cyclin D1 and elevated β-catenin expression [149](Fig 3). In cyst fluid and kidney epithelial cells of ADPKD patients, high level accumulation of macrophage migration inhibitory factor (MIF) was found [150]. MIF may activate PI3K/Akt pathway and subsequently inhibit GSK3β [151]. In a parallel observation, MIF stimulates cytokine initiation and expansion via p-ERK/mTOR mediated cell proliferation pathway [150]. Thus, PI3K/Akt/p-ERK/mTOR axis participates a crucial role for polycystic kidney formation [152]. To view another aspect, young ADPKD patients with normal blood pressure and renal function exhibit early vascular changes and bi-ventricular diastolic dysfunction [153,154]. From clinical studies reveal that ADPKD has higher association with hypertension, left ventricular hypertrophy and cerebral aneurysms [155,156]. Mutations in PKD1 and PKD2 genes are known to account for ADPKD. PKD1 mutations account for ~85% and PKD2 mutations for ~15% of cases [157]. PKD1 and PKD2 encode the polycystin-1 (PC1) and polycystin-2 (PC2), respectively. PC1 interacts with PC2 and function as non-selective calcium-regulated cation channel [158]. Polycystic kidneys contain higher level of macrophages. Given the potential signal for increased macrophage numbers in cystic kidneys, animal studies show that MCP-1 is highly upregulated as cyst expansion in PKD1 and PKD2 knockout mice [159]. Moreover, tubular cell is reported to be the major source of MCP1 [160] and converted M2 macrophages could initiate renal cysts and tubule epithelial cells proliferation. However, M1 macrophages reveals limited proliferation promotion effects [161]. Moreover macrophages also participate MCP-1 production in an activated Akt and phosphorylated GSK3β-dependent manner [14](Fig. 3).

4.5. GSK3β in aneurysm

Polycystin 1 and polycystin 2, two essential protein products of PKD1 and PKD2 respectively, are expressed in vascular smooth muscle and endothelium. Thus, interactions of these proteins with a hereditary Fig. 3. The role of phosphorylated GSK3β on polycystin-1/2 mutation of polycystic kidney disease. MIF stimulates cytokine initiation and expansion via p-ERK/mTOR mediated cell proliferation pathway. GSK3β inhibitor (TDZD-8) or berberine may decrease renal cell proliferation and cyst expansion via p-ERK/p70S6/c-Myc/Cyclin D1/β-catenin modulation. From the macrophage aspect, high level of MIF in cyst modulate PI3K/Akt/GSK3β/MCP-1 axis and promotes renal tubule cell proliferation and cyst expansion. Phosphorylated GSK3β (inactive form) results in MCP-1 production and β-catenin activation during the process of vascular remodeling and aneurysm. M1/ M2 macrophages participates in different stages of aneurysm development. Long-term lithium treatment may influence podocyte cell cycle and renal function by GSK3β suppression (phosphorylated form). GSK3β degradation by microRNA-92a triggers podocyte re-entry cell cycle and renal failure via Ajuba and YAP/TAZ signal pathway.
pathological pathway might be the underlying mechanism involved in the early development of vascular remodeling and aneurysms in ADPKD [162,163]. This could be explained for why many extrarenal manifestations, especially in those of cardiovascular and cerebrovascular abnormalities, are found in associated with ADPKD. Intracranial aneurysm, a cerebrovascular disorder with weakness cerebral vessel, leads to a localized dilation or ballooning of this vessel. Because macrophages are universal finding in human intracranial aneurysm samples, the infiltration of macrophages secrete proinflammatory cytokines and MMPs. This aneurysm localized effect could recruit additional inflammatory cells and destroy extracellular matrix of arterial wall [98]. In addition, abdominal aortic aneurysm tissue is also indicated accumulating macrophages has been considered as an important source of matrix-degrading proteases and to degrade the extracellular matrix. The role of MMPs in preclinical models of abdominal aortic aneurysm is well established [164] and in human abdominal aortic aneurysm as well [165]. In general there are two primarily sources of endogenous elastases (neutrophils and macrophages). The neutrophil elastase is an intracellular, granule-associated enzyme and macrophage elastase appears to be a secretory enzyme. Unstimulated macrophages secrete very little elastase activity but can be triggered to secrete higher levels of this enzyme by phagocytosis [166] [167]. By utility of elastase-induced abdominal aortic aneurysm, it appears that M1 macrophages predominate in early stages of aneurysm development while M2 macrophages accumulate at late stage [168] [169] (Fig. 3). Further analysis, IL-23 blockade inhibits the expansion of macrophages and profoundly reduced the expression of macrophage-associated inflammatory mediators. The primarily source of IL-23 is derived from macrophages and dendritic cells [170]. The IL-12/IL-23 axis participate in human abdominal aortic aneurysm and this signal transduction is conceived as a potential therapeutic pathway [171]. In angiotensin II-induced aortic aneurysm, the suprarenal aortas samples appear higher phosphorylation of GSK3β and activated Wnt signaling (Fig. 3). Moreover sclerostin is an inhibitory molecule of the Wnt/β-catenin signaling pathway [172] and sclerostin reduction is observed in aortic aneurysm. Sclerostin may protect AngII-infused mice from macrophage infiltration [173]. Of particular higher phosphorylated GSK3β leading to β-catenin activation is found on aneurysm [173]. Thus, inhibition of GSK3β by lithium has been shown to activate Wnt pathway and promote endothelial cell senescence [174]. It is also the evidence of arterial aging that Wnt/β-catenin activation is involved in vascular smooth muscle cells resting transformation [175]. From the anti-sclerostin antibody (Romosozumab) clinical trial for osteoporosis, it indicates high risk of cardio-vascular events and remodeling, implying Wnt/β-catenin activation [176]. This could explain the role of sclerostin reduction in aortic aneurysm, where Wnt/GSK3β/β-catenin might promote the senescent phenotypes of arterial cells.

4.6. GSK3β in renal cells

Specifically deletion of GSK3 in podocytes of mice could result into a spectrum of kidney disease, ranging from albuminuric mesangial hyper-cellularity to glomerulosclerosis, severe hypertension and renal failure. The rationale of crescentic glomerulopathy is the mature podocyte to re-enter the cell cycle and proliferate. Some evidences indicate that terminally differentiated podocytes can re-enter the cell cycle in response of inflammatory glomerulonephritis [177] and HIV activated pathway of Wnt signaling in nephropathy [178]. Since podocytes may prevent albuminuria and preserve renal function, its well differentiated phenotypes are of significance [179,180]. On the disease setting, podocytes initiate mitosis with incompletely division by mitotic catastrophic mechanism. This insult may lead to crescentic rapidly progressive glomerulonephritis (RPGN) [181]. In addition, much higher level expression of GSK3β and phosphorylated form have linked to progression of albuminuria and diabetic kidney injury. Further analysis, renal glomeruli and tubules manifest higher phosphorylated GSK3β(Tyr216) [182]. Since there are many comorbidities associated with diabetes, the function of GSK3β in kidney could be conceived with more attention during disease or therapy-related renal function interference [183,184]. Particularly, recent approach using detection of GSK3β activity in urinary exfoliated cells for early evaluation renal function in diabetic patients [182].

4.7. GSK3β in podocyte cell re-entry

Among the patients diagnosed with crescentic RPGN, elevated miR-92a is observed in kidney biopsies, particularly the field with podocytes. As a result, by means of specific abrogating miR-92a in podocyte, it reduces albuminuria and kidney failure [185]. (Fig. 3). As a result, podocyte exhibits cell cycle arrest mediated by p57kip2 regulation after inhibiting miR-92a. It is noticed that GSK3β appears to act as a direct target of miR-92a and triggers downstream β-catenin activation [186,187]. Furthermore, attenuated GSK3 results in the expression of Ajuba and accordingly nucleus YAP/TAZ, accumulation contributes cell cycle re-entry and mitotic catastrophe [188] (Fig. 3). It is believed that inhibiting podocyte GSK3β activity exhibits beneficial renal diseases treatment [189]. Lithium is a prescribed medicine for bipolar disorder and is found to inhibit estimated 25% of GSK3 activity at the bio-available dose [190]. For long term administration of lithium on patients or animal models, renal side effects could be observed, such as diabetes insipidus, and an increased principal cell proliferation [191] [192,193].

4.8. GSK3β in renal protection

Given certain therapy-induced kidney adverse effects, podocyte dysfunction has been regarded as a critical role. Adriamycin elicits prominent oxidative stress and alters the activity of redox-sensitive kinases in target organs, such as kidneys. It reports that glomerular staining of podocyte marker (podocin and WT-1) decreased following adriamycin injury. Adriamycin exposure consistently diminished protein expression levels of podocin and WT-1, suggesting podocyte influence. The adriamycin-induced podocyte injury was followed by overactivity of GSK3β in the glomerulus [189]. By using GSK3β inhibitor, TJDZ-D-B reduces the adriamycin-ciliated GSK3β overactivity and increased expression of podocin and WT-1 in glomerulus [161,194]. Attenuation of GSK3 has been shown to reduce proteinuria, podocyte injury and glomerulosclerosis in the experimental model of diabetic nephropathy [195], podocytopathy elicited by adriamycin and LPS treatment [189,196]. GSK3β was found to phosphorylate serine 467 of NFkB and then involves in transcription of podocyte cytoskeleton re-arranged genes (MCP-1, B7-1, and cathepsin L) [196,197].

Berberine reduces cell growth in autosomal dominant polycystic kidney disease (ADPKD) cystic cells by cell cycle G0/G1 arrest and p-ERK/p70-S6 reduction (a downstream kinase of mTOR) [198]. Furthermore, berberine attenuates macrophages infiltration in intracranial aneurysms [199]. Previous reports have demonstrated the berberine anti-inflammatory effects are mediated by inhibiting several key signaling pathways involved in macrophages infiltration, such as Nr22 and MAPK/JNK/p38/ERK pathway [72,200] and SRC-FAK pathway [201]. FAK/PYK2 may phosphorylate GSK3β(Tyr216) and to stabilize β-catenin [202]. Phosphorylation of GSK3β(Tyr216) is required for GSK3β's full kinase activity [203]. Berberine may inhibit FAK phosphorylation in macrophages [199,204]. Converging all these evidences, it reveals that berberine inhibits cyst and macrophage infiltration via FAK/GSK3β(Tyr216)/β-catenin modulation (Fig. 3).

5. Concluding remarks

GSK3 activity is required in physiological settings and interfering its function is associated in many diseases. Here we describe macrophages participating on acute respiratory distress syndrome by GSK3β
activation and differently regulated transcription factor NFkB or CREB-mediated M1 macrophage pro-inflammation or M2 macrophage anti-inflammatory responses, respectively. In the setting of myocarditis, GSK3β cooperates with JNK1 to trigger NLRP3/caspase-1-IL-1β-related inflammation. As for the chronic inflammation in heart, secreted HMG1 induces MMP9-related cell remodeling and highly MDR1 expression on M2 macrophages involve in dilated cardiomyopathy. For inherited genetic disturbance of polycystin-1/2 on polycystic kidney disease, Akt/GSK3β axis modulation results in MCP-1 production in macrophages. M2 macrophage enhances renal tubule cell proliferation.

The polycystin-1/2 mutations manifested vascular remodeling and an- mackrophages. M2 macrophage enhances renal tubule cell proliferation.


declaration of competing interest

W.-L. Liu, et al.

[11] K. MacAulay, et al., Glycogen synthase kinase 3 (GSK3) mediates M1 macrophage pro-inflammatory cytokine production in response to lipopolysaccharide (LPS) stimulation. J. Immunol. 161 (7) (Mar.2003) 3232–3239, https://doi.org/10.4049/jimmunol.161.7.3232.

[12] Y. Zhao, et al., Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury, Am. J. Phys. Lung Cell. Mol. Phys. 295 (3) (Sep.2008) L497–L504, https://doi.org/10.1152/ajplung.90210.2008.

[13] T. Suzuki, et al., Inhibition of AMPK catalytic action by GSK3, Mol. Cell 50 (2013) 407–419, https://doi.org/10.1016/j.molcel.2013.02.022.

[14] C. Gorrizieri, et al., 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-3-H-pyrole-2,5-dione (SR216763), a glycogen synthase kinase-3 inhibitor, displays therapeutically apetuous properties in a mouse model of pulmonary inflammation and fibrosis, J. Pharmacol. Exp. Ther. 332 (3) (Mar.2010) 785–794, https://doi.org/10.1124/jpet.109.153640.

[15] R.H. Hastings, H.G. Folkesson, M.A. Matthay, Mechanisms of alveolar protein clearance in the intact lung, Am. J. Phys. Lung Cell. Mol. Phys. 286 (4) (Apr.2004) L679–L689, https://doi.org/10.1152/ajplung.90210.2008.

[16] C.J. Doehl, et al., Restoration of megalin-mediated clearance of alveolar protein as a novel therapeutic approach for acute lung injury, Am. J. Respir. Cell. Mol. Biol. 57 (5) (2017) 589–602, https://doi.org/10.1165/rcmb.2016-0558OC.

[17] O. Hoffmann, N. Burns, I. Vadilaz, H.K. Eltzschig, M.G. Edwards, C.J. Doehl, Detrimental ELAVL-1/HuR-dependent GSK3β mRNA stabilization impairs resolution in acute respiratory distress syndrome, PLoS One 12 (2) (2017) e0172116, https://doi.org/10.1371/journal.pone.0172116.

[18] M.I. Yusef, et al., Crellin-expressing thalamus regulates neuronal activity in brain plasticity and behavior through the activation of the inhibitory interneurons, J. Neurosci. 34 (36) (Sep.2014) 11906–11916, https://doi.org/10.1523/jneurosci.3146-14.2014.

[19] S. Finocchiaro, et al., The demonstration of an endogenous role for ibotenic acid in LTP induction and LTD suppression, J. Neurosci. Res. 71 (4) (Aug.2003) 506–514, https://doi.org/10.1002/jnr.10486.

[20] J. Werner, K. Zgraggen, C. Fernández-del Castillo, K.B. Levandowski, C.C. Compton, A.L. Warshaw, Specific therapy for local and systemic complications of acute pancreatitis with monoclonal antibodies against ICAM-1, Ann. Surg. 229 (6) (Jun.1999) 834–840 (discussion 841-2), https://doi.org/10.1097/00000658-199906000-00015.
expression and promotes muscle injury repair, Proc. Natl. Acad. Sci. 106 (4) (Oct.2009) 17475-17480, https://doi.org/10.1073/pnas.0908641106.

A. J. Walkley and R. S. Wiener, “Macrolide antibiotics and survival in patients with acute lung injury,” Chest, vol. 141, no. 5, pp. 1153-1159, May 2012, doi:10.1378/chest.11-1298.

D. Amantia et al., “Asthmocin prevents mice against ischemic stroke injury by promoting macrophage transition towards M2 phenotype.” Exp. Neurol., vol. 275 Pt 1, pp. 116-25, Jan. 2016, doi:10.1016/j.expneurol.2015.10.016.

Y. Liu, et al., Protective effect of minocycline against ketamine-induced injury in neural stem cell: involvement of P38/Akt and AKT-3 Beta pathway, Front. Mol. Neurosci. 9 (2016) 135, https://doi.org/10.3389/fnmol.2016.00135.

G. L. Chen, J.L. Pomerantz, D.B. Grossman, J.E. Clements et al., Suppression of nuclear factor of activated T cells 1 (NFAT1) in human CD4+ Tcells, J. Biol. Chem. 283 (11) (Apr. 2011) 11275-11282, https://doi.org/10.1561/12712.

Y. Liang, et al., Berberine ameliorates lipopolysaccharide-induced acute lung injury via the PERK-mediated Nrf2/HO-1 signaling axis, Phytother. Res. 33 (1) (Jan. 2019) 130-148, https://doi.org/10.1002/ptr.6206.

S. M. J. Ahmed, L. Luo, A. Namani, K. J. Wang, X. Tang, Nrf2 signaling pathway: pivotal roles in inflammation, Biochim. Biophys. Acta Mol. Basis Dis. 1863 (2) (2017) 585–597, https://doi.org/10.1016/j.bbadis.2016.11.005.

S. Das, R.S. Samant, L.A. Sheved, Nonclassical activation of HEDGEhog signaling enhanced multidrug resistance and makes breast cancer cells refractory to estrogen-targeting HEDGEhog inhibition, J. Biol. Chem. 288 (17) (Apr. 2013) 11824-11833, https://doi.org/10.1074/jbc.M111.342302.

W. Shang, J. Liu, X. Yu, J. Zhao, Effects of berberine on serum levels of inflammatory factors and IL-6 signaling pathway in ischemia reperfusion injury induced by high fat diet, Zhongguo Zhong Yao Za Zhi 35 (11) (Jun.2010) 1477-1477.

G. Cui, X. Qin, Y. Zhang, G. Be, Y.Q. Zang, Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 cell differentiation in type 1 diabetic mice, J. Biomed. Sci. 24 (4) (Oct. 2009) 2840-2849, https://doi.org/10.1007/s10071-012-1674-z.

Y. C. Song, et al., Berberine regulates melanin synthesis by activating PI3K/AKT, ERK and GSK3β in B16F10 melanoma cells, Int. J. Mol. Med. 35 (4) (Apr. 2015) 931-938, https://doi.org/10.3892/ijmm.2015.2113.

A.B. Chai, A.J. Ammit, I.C. Gelissen, Examining the role of ABC lipid transporters in pulmonary lipid homeostasis and inflammation, Respir. Rev. 18 (1) (2017) 41-47, https://doi.org/10.1007/s11959-017-0161-6.

J. C. Lim, Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells, J. Neurochem. 106 (4) (May 2009) 1301-1310, https://doi.org/10.1111/j.1471-4159.2009.05373.x.

M. Leost, et al., Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25, Eur. J. Biochem. 267 (19) (Oct. 2000) 5983-5994, https://doi.org/10.1046/j.1432-1033.2000.01673.x.

H. L. Lin, T.Y. Liu, W. L. Yu, and C. W. Chi, “Up-regulation of multidrug resistance transporter expression in human and murine hepatoma cells,” Cancer, vol. 85, no. 9, pp. 1957-42, May 1999.

H. L. Lin, T.Y. Liu, C.W. Wu, C.W. Chi, Berberine modulates expression of mdrl gene product and the responses of digestive tract cancer cells to paclitaxel, Br. J. Cancer, vol. 78, no. 6, pp. 739-45, Mar. 1998, https://doi.org/10.1054/bjcan.1998.0343.

R. Kerkela, et al., Deletion of GSK-3β in mice leads to hyperthermic cardiomyopathy secondary to cardiomyoblast hyperproliferation, J. Clin. Invest. 118 (11) (Nov. 2008) 3609-3618, https://doi.org/10.1172/JCI36245.

A. L. Caofer, R. Montagono, R. Johns, M. P., S. B. Felix, S. Iliecu, Immuno-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management, Heart Fail. Rev. 16 (2) (Nov. 2011) 715-732, https://doi.org/10.1007/s10741-011-9364-5.

I. Müller, et al., Pathogenic role of the damage-associated molecular patterns S100A8 and S100A9 in Coxsackievirus B3-induced Myocarditis, Circ. Heart Fail. 10 (11) (Nov. 2017), https://doi.org/10.1161/CIRCHEARTFAILURE.117.004125.

J.C. Simard, et al., S100A8 and S100A9 induce cytokine expression and regulate the NF-κB inflammatory-dependent activation of NF-κB-1, PLoS One 8 (8) (2013) e72138, https://doi.org/10.3389/fimmu.2017.0072138.

C. Tschöpe, et al., NOD2 (nucleotide-binding oligomerization domain 2) is a major pathogenic mediator of coxsackievirus B3-induced myocarditis, Circ. Heart Fail. 9 (3) (2016) 1436-1447, https://doi.org/10.1161/CIRCHEARTFAILURE.115.003870.

J. Tschopp, K. Schroder, NLRP3 in inflammatory signaling pathway in obese mice induced by high fat diet, Zhongguo Zhong Yao Za Zhi 35 (11) (Jun.2010) 1477-1477.

N. Song, et al., NLRP3 phosphorylation is an essential priming event for in- inflammasome activation, Cell 164 (1) (Jan. 2016) 1421-1436, https://doi.org/10.1016/j.cell.2016.04.015.

W. Wei, et al., Lupus-like inflammatory response via inhibiting the activation of NLRP3 inflammasome, J. Immunol. 196 (2) (Oct. 2016) 796-806, https://doi.org/10.4049/jimmunol.1600518.

C. Tschöpe, T. Cooper, G.Torre-Amione, and S. Van Linthout, "Management of
myocarditis-related cardiomyopathy in adults," Circ. Res., vol. 124, no. 11, pp. 1568–1583, May 2019, doi:10.1161/CIRCRESAHA.118.315758.

[93] X. Hou, et al., The cardiac microenvironment interacts with various monocytes and functions in myocarditis, Cell Rep. 28 (1) (Jul. 2019) 172–189.e7, https://doi.org/10.1016/j.celrep.2019.06.007.

[94] J.G. Barin, N.R. Rosefield, D. Macrophage diversity in cardiovascular disease: a review, Immunobiology 217 (5) (May 2012) 468–475, https://doi.org/10.1016/j.imb.2011.06.001.

[95] T. Takahashi, K.E. Borońfeld, Macrophage phenotype and function in different stages of atherosclerosis, Circ. Res. 118 (4) (Feb. 2016) 653–667, https://doi.org/10.1161/CIRCRESAHA.115.306256.

[96] E.A. Fisher, Regression to atherosclerosis: the journey from the lumen to the plaque and back, Arterioscler. Thromb. Vasc. Biol. 36 (2) (Feb. 2016) 226–235, doi:10.1161/ATVHA.115.301926.

[97] M. Laplante, D.M. Sabatini, mTOR signaling in growth control and disease, Cell 150 (2012) 911–925, doi:10.1016/j.cell.2012.05.003.

[98] Y. Kanematsu, et al., Critical roles of macrophages in the formation of intracranial aneurysm, Stroke 42 (1) (Jan. 2011) 173–178, https://doi.org/10.1161/STROKEAHA.110.599076.

[99] L. Caserta, E. Cass, G. Poli, Macrophage polarization in health and disease, Sci. World J. 11 (2011) 2391–2402, https://doi.org/10.1100/2011/23962.

[100] M. Takahashi, Eosinophilic myocarditis, Thorax 60 (9) (Sep. 2005) 816–818, https://doi.org/10.1136/thx.2005.03706.

[101] A.Deb, Y.-H. Liao, et al., Interleukin-17A contributes to myocardial ischemia/reperfusion injury, Circ. Res., vol. 106, no. 10, pp. 239–247, https://doi.org/10.1161/CIRCRESAHA.115.304033.

[102] S.K. Jorch, et al., An emerging role for neutrophil extracellular traps in non-inflammatory responses, J. Pharmacol. Exp. Ther. 366 (2) (Aug. 2018) 332–341, https://doi.org/10.1124/jpet.178.211821.

[103] T. Takahashi, et al., Cardiac nuclear high-mobility group box 1 ameliorates pathological cardiac hypertrophy by inhibiting DNA damage response, JACC. Basic Transl. Sci. 3 (4) (Apr. 2019) 234–247, https://doi.org/10.1016/j.jacbts.2018.11.011.

[104] D.C. Cascone, et al., Human ventricular unloading induces cardiomyocyte proliferation, J. Am. Coll. Cardiol. 65 (9) (Mar. 2015) 892–900, https://doi.org/10.1016/j.jacc.2014.12.037.

[105] T. Takahashi, et al., Cardiac nuclear high-mobility group box 1 ameliorates pathological cardiac hypertrophy by inhibiting DNA damage response, JACC. Basic Transl. Sci. 3 (4) (Apr. 2019) 234–247, https://doi.org/10.1016/j.jacbts.2018.11.011.

[106] N. Neu, R. Klieber, M. Frühwirth, P. Berger, Cardiac myosin-induced myocarditis as a model of postinfectious autoimmunity, Eur. Heart J. 12 (Suppl. 1) (Aug. 1991) 117–120, https://doi.org/10.1093/eurheartjr/12.suppl_d.117.

[107] L.T. Weckbach, et al., Medine drives cardiac inflammation by promoting neutrophil trafficking and neutrophil-dependent myocarditis, J. Exp. Med. 216 (2) (2019) 350–368, https://doi.org/10.1084/jem.20181102.

[108] J.L. Dunne, C.M. Ballantyne, A.L. Beaudet, K. Ley, Control of leukocyte rolling velocity in TNF-a-induced inflammation by LFA-1 and Mac-1, Blood 99 (1) (Apr. 2002) 336–341, https://doi.org/10.1182/blood.v99.1.336.

[109] S.K. Jorch, et al., An emerging role for neutrophil extracellular traps in non-inflammatory disease, Nat. Med. 23 (2017) 279–287, https://doi.org/10.1038/nm.4354.

[110] L.T. Weckbach, et al., Blocking LFA-1 aggravates cardiac inflammation in experimental autoimmune myocarditis, Cells 8 (10) (2019), doi:10.3390/cells810267.

[111] S. Su, H. Zhou, J. Wang, ALX and CD11b: a ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense, Nat. Commun. 9 (1) (Dec. 2018) 525, https://doi.org/10.1038/s41467-018-02896-8.

[112] T.K. Kishimoto, N. Holland, T.M. Roberts, D.C. Anderson, T.A. Springer, Heterogeneous mutations in the beta subunit common to the LFA-1, Mac-1, and p150,95 glycoproteins cause leukocyte adhesion deficiency, Cell 50 (2) (Jul. 1987) 193–202, https://doi.org/10.1016/s0002-9440(87)80215-7.

[113] C.T. Letof, K. Ley, Neutrophil arrest by LFA-1 activation, Front. Immunol. 3 (2012) 157, https://doi.org/10.3389/fimmu.2012.00157.

[114] Y. Su, S.M. Qadry, F.S. Cayabyab, M. Liu, W. Le, L.E. Liu, Regulation of myocardial ischaemic-reperfusion injury by endothelial SGLK1/SGLK3 signaling, Biochim. Biophys. Acta. Mol. Cell Res. 1843 (11) (Nov. 2014) 2481–2491, https://doi.org/10.1016/j.bbamcr.2014.09.038.

[115] P.S. Olofsson, M. Rosas-Ballina, Y.A. Levine, K.J. Tracey, Rethinking inflammation: neural circuits in the regulation of immunity, Immunol. Rev. 248 (1) (2012) 188–204, https://doi.org/10.1111/j.1600-065X.2011.01318.x.

[116] H. Han, et al., Nck2 serine-arginine rich nuclear GTPase receptor of subunit is an essential regulator of inflammation, Nature 421 (6921) (Jan.2003) 384–388, https://doi.org/10.1038/nature01439.

[117] C. Rocha-Resende, et al., Non--neurogenic cardiac machinery present in cardiac myocytes offsets hypoxia signals, J. Mol. Cell. Cardiol. 53 (2) (Aug. 2012) 206–216, https://doi.org/10.1016/j.yjmcc.2012.05.003.

[118] A. Roy, et al., Cardiac acetylcholine inhibits ventricular remodeling and dysfunction through autophagic pathways, J. Am. Coll. Cardiol. 73 (2019) 3020–3035, https://doi.org/10.1016/j.jacc.2019.02.72604.

[119] Y. Kanematsu, A. Kiyakma, T. Sato, Cholinoinceptive and cholinergic properties of cardiomyocytes involving an amplification mechanism for vagal effector effects in sparsely innervated ventricular myocardium, FEBS J. 276 (18) (Sep.2009) 5111–5125, doi:10.1111/j.1742-4658.2009.07208.x.

[120] J.A. Rocha, et al., Involvement of the Wnt signaling pathway in cardiac remodeling and hypertrophic signal pathways in mice, J. Am. Coll. Cardiol. 50 (10) (May 2007) 1127–1134, https://doi.org/10.1016/j.jacc.2007.02.049.

[121] D.C. Canseco, et al., Human ventricular unloading induces cardiomyocyte proliferation, J. Am. Coll. Cardiol. 65 (9) (Mar. 2015) 892–900, https://doi.org/10.1016/j.jacc.2014.12.037.
H. Yan, Y. Hu, A. Akk, K. Ye, J. Bacon, C.T.N. Pham, Interleukin-12 and -23 blockade mitigates elastase-induced abdominal aortic aneurysm, Sci. Rep. 9 (1) (Dec. 2019) 10447, https://doi.org/10.1038/s41598-019-46909-y.

M.J.C. Moester, S.E. Papopoulos, C.W.G.M. Löffler, R.L. van Boezooijen, Sclerostin: current knowledge and future perspectives, Calcif. Tissue Int. 87 (2) (Aug. 2010) 167–176, https://doi.org/10.1007/s00223-010-9589-0.

S.M. Krishna, et al., Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 37 (3) (Mar. 2017) 553–566, https://doi.org/10.1161/ATVBAHA.116.308210.

C.D. Mao, P. Hoang, P.E. Di Corleto, Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells, J. Biol. Chem. 276 (28) (Jul. 2001) 26818–26826, https://doi.org/10.1074/jbc.M111862200.

A. Marchand, et al., The Wnt/beta-catenin pathway is activated during advanced arterial aging in humans, Aging Cell 10 (2) (Apr. 2011) 220–232, https://doi.org/10.1111/j.1474-9726.2010.00691.x.

K. Andojooya, A. Witek, Cardiovascular outcomes of rosmozumab and protective role of alemtuzumab, Arterioscler. Thromb. Vasc. Biol. 39 (7) (Jul. 2019) 1343–1350, https://doi.org/10.1161/ATVBAHA.119.312371.

M.J. Moeller, Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis, J. Am. Soc. Nephrol. 15 (1) (Jun. 2004) 61–67, https://doi.org/10.1097/01.asn.0000100246.38709.c6.

M. Shikredi, et al., Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling, Nat. Med. 18 (1) (Jan. 2012) 111–119, https://doi.org/10.1038/nm.2468.

K. Hiromura, et al., Podocyte expression of the CDK-inhibitor p57 during development and disease, Kidney Int. 60 (Dec. 2001) 2235–2246, https://doi.org/10.1046/j.1523-1755.2001.00597.x.

L. Angiolini, M. Mokravets, M. Nagata, H. Yamase, P. Mundel, Podocyte cell cycle regulation and proliferation in collapsing glomerulonephropathies, Kidney Int. 58 (1) (Jul. 2000) 137–143, https://doi.org/10.1038/ki.2000.2103.

K. Nitta, et al., Glomerular expression of cell-cycle-regulatory proteins in human crescentic glomerulonephritis, Am. J. Kidney Dis. 43 (5) (Oct. 1999) 422–427, https://doi.org/10.1053/ajkd.1999.04020.

Z. Liang, et al., Glycogen synthase kinase 3β hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease, Kidney Int. 97 (1) (Jan. 2020) 175–192, https://doi.org/10.1016/j.kint.2019.08.036.

K-U. Eckardt, et al., Evolving importance of kidney disease: from subspecialty to global health burden, Lancet 382 (9887) (2013) 158–169, https://doi.org/10.1016/S0140-6736(13)60235-5.

M. Tonelli, et al., Chronic kidney disease and mortality risk: a systematic review, J. Am. Soc. Nephrol. 17 (7) (Jul. 2006) 2034–2047, https://doi.org/10.1681/ASN.2005100108.

C. Henique, et al., Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis, Nat. Commun. 8 (Dec. 2017) 1218–1218, https://doi.org/10.1038/s41467-017-01885-7.

H. Wang, et al., MicroRNA-92 promotes invasion and chemoresistance by targeting GSK3β and activating Wnt signaling in bladder cancer cells, Tumour Biol. 37 (12) (Dec. 2016) 16295–16304, https://doi.org/10.1007/s13277-016-5460-9.

G-J. Zhang, et al., MiR-92a promotes stem cell-like properties by activating Wnt/R-cadherin signaling in colon cancer, Oncotarget 8 (60) (Nov. 2017), https://doi.org/10.18632/oncotarget.22698.

J.A. Hurcombe, et al., Podocyte GS3K is an evolutionarily conserved critical regulator of kidney function, Nat. Commun. 10 (1) (Dec. 2019) 403, https://doi.org/10.1038/s41467-019-11930-4.

Z. Wang, H. Bao, Y. Ge, S. Zhuang, A. Peng, R. Gong, Pharmacological targeting of GS3Kβ confers protection against podocytopenia and proteinuria by desensitizing mitochondrial permeability transition, Br. J. Pharmacol. 172 (3) (Feb. 2015) 1206–1218, https://doi.org/10.1111/bph.12952.

O. Kaidanovich-Beilin, J.R. Woodgett, GS3K-β functional insights from cell biology and animal models, Front. Mol. Neurosci. 4 (2011), https://doi.org/10.3389/fnmol.2011.00040.

H. Aif, et al., Effects of 10 to 30 years of lithium treatment on kidney function, J. Psychopharmacol. 29 (5) (May 2015) 601–614, https://doi.org/10.1177/026988115573808.

H. Bendz, S. Schön, P-O. Attman, M. Aurell, Renal failure occurs in chronic lithium treatment but is uncommon, Kidney Int. 77 (3) (Feb. 2010) 219–224, https://doi.org/10.1038/ni.2005121355.

B.M. Christensen, Y.-H. Kim, T.-H. Kwon, S. Nielsen, Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct, Am. J. Physiol. 291 (1) (Jul. 2006) F39–F48, https://doi.org/10.1152/ajprenal.00412.2005.

D.R. Perrone, A.M. Malek, T. Watnick, Vascular complications in autosomal dominant polycystic kidney disease, Kidney Int. 87 (6) (Jun. 2015) 1175–1185, https://doi.org/10.1038/ki.2014.427.

J. Ai, et al., Genetic risk score for advanced glomerular sclerosis in collapsing glomerulopathy, Kidney Int. 83 (3) (Sep. 2013) 143, https://doi.org/10.1038/ki.2014.428.

R. Thompson, et al., Immunohistochemistry analysis of Podocalyxin-like protein 1 in kidneys and animal models, Front. Mol. Neurosci. 4 (2011), https://doi.org/10.3389/fnmol.2011.00039.

M.F. Cassini, et al., Mcp1 promotes macrophage-dependent cyst expansion in autosomal dominant polycystic kidney disease, J. Am. Soc. Nephrol. 29 (10) (Oct. 2018) 2471–2487, https://doi.org/10.1681/ASN.2017050518.

C.-L. Lin, J.-Y. Wang, Y.-T. Huang, Y.-H. Kuo, K. Surendran, F.-S. Wang, Wnt/b-catenin signaling modulates survival of high glucose-stressed mesangial cells, J. Am. Soc. Nephrol. 17 (10) (Oct. 2006) 2812–2820, https://doi.org/10.1681/ASN.2005121355.

H. Bao, Y. Ge, A. Peng, R. Gong, Fine-tuning of Nfκb by glycogen synthase kinase 3β directs the fate of glomerular podocytes upon injury, Kidney Int. 87 (6) (Jun. 2015) 1176–1190, https://doi.org/10.1038/ki.2014.426.

C.Li, Y.Ge, L.Dworkin, A.Peng, and R. Gong, “The β isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy,” J. Pathol., vol. 239, no. 1, pp. 23–35, May 2016, doi: 10.1002/path.4692.

A. Bonon, A. Mangolini, P. Pinton, L. de Senno, G. Aguiari, Berberine slows cell...
growth in autosomal dominant polycystic kidney disease cells, Biochem. Biophys. Res. Commun. 441 (3) (Nov.2013) 668-674, https://doi.org/10.1016/j.bbrc.2013.10.076.

[199] K. Quan, et al., Berberine attenuates macrophages infiltration in intracranial aneurysms potentially through FAK/Grp78/UPR axis, Front. Pharmacol. 9 (May 2018), https://doi.org/10.3389/fphar.2018.00565.

[200] M. Gao, L. Chen, L. Yang, X. Yu, J. Kou, B. Yu, Berberine inhibits LPS-induced TF procoagulant activity and expression through NF-κB/p65, Akt and MAPK pathway in THP-1 cells, Pharmacol. Rep. 66 (3) (Jun.2014) 480–484, https://doi.org/10.1016/j.pharep.2013.12.004.

[201] W.-E. Cheng, M. Ying Chang, J.-Y. Wei, Y.-J. Chen, M.-C. Maa, T.-H. Leu, Berberine reduces Toll-like receptor-mediated macrophage migration by suppression of Src enhancement, Eur. J. Pharmacol. 757 (Jun.2015) 1-10, https://doi.org/10.1016/j.ejphar.2015.03.013.

[202] C. Gao, G. Chen, S-F. Kuan, D.H. Zhang, D.D. Schlaepfer, J. Hu, FAK/PTK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β, Elife 4 (Sep. 2015), https://doi.org/10.7554/eLife.10072.

[203] K. Hughes, E. Nikolakaki, S.E. Plyte, N.F. Totty, J.R. Woodgett, Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation, EMBO J. 12 (2) (Feb.1993) 803-808.

[204] J. Tang, et al., CD147 induces UPR to inhibit apoptosis and chemosensitivity by increasing the transcription of Bip in hepatocellular carcinoma, Cell Death Differ. 19 (11) (Nov.2012) 1779–1790, https://doi.org/10.1038/cdd.2012.60.